Healthtech funding in H2 2021
European Healthtech startup funding raised during H2 2021.
In H2 2021, 371 European Healthtech companies closed 376 funding rounds and raised €5.7B in equity funding (excluding debt and grants), up 57.0% versus H2 2020. Debt rounds added €23M. UK led by capital raised, and Sofinnova Partners was the most active investor. Data as of 20 Nov 2026.
Equity funding
€5.7B
+57.0% vs H2 2020 · excl. debt & grants · +€23M debt
Funding rounds
376
+19.4% vs H2 2020
Companies
371
Top country
UK
Rank among sectors
#4
7.4% of sector funding
Debt financing
€23M
0.4% of total
Top-10 round share
31.9%
of disclosed capital
Rounds ≥ €100M
11
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2021 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €1.2B | 78 |
| Aug | €706M | 51 |
| Sep | €894M | 63 |
| Oct | €854M | 65 |
| Nov | €1.0B | 61 |
| Dec | €1.0B | 58 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2021 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2021 | |
|---|---|
| UK | €2.2B |
| France | €830M |
| Germany | €625M |
| Switzerland | €493M |
| Czech Republic | €280M |
| Netherlands | €277M |
| Sweden | €224M |
| Belgium | €174M |
Stage mix
by € raisedHealthtech — stage mix, H2 2021 — interactive chart.
Data table
| Healthtech — stage mix, H2 2021 | |
|---|---|
| Other | €2.4B |
| Series B | €1.3B |
| Series D+ | €728M |
| Series C | €564M |
| Series A | €534M |
| Seed | €147M |
| Growth/Late | €42M |
| Debt | €23M |
| Pre-Seed | €18M |
| Crowdfunding | €17M |
| Grant | €4.2M |
| Early VC | €1.0M |
Exits & M&A
24 Acquisition · 2 IPO26 exits · €1.8B disclosed.
| BenevolentAI | IPO | Dec 2021 | €435M |
| Current Health | Acquisition | Nov 2021 | €357M |
| Simbionix | Acquisition | Jul 2021 | €256M |
| Sanifit | Acquisition | Nov 2021 | €205M |
| Bicycle Therapeutics | IPO | Oct 2021 | €173M |
| Zebra Medical Vision | Acquisition | Aug 2021 | €171M |
Top deals
largest disclosed rounds in H2 2021| Company | Stage | Date | Amount |
|---|---|---|---|
| CMR Surgical | Series D+ | Jul 2021 | €505M |
| Sotio Biotech | Other | Dec 2021 | €280M |
| Owkin | Other | Nov 2021 | €159M |
| Sword Health | Series D+ | Nov 2021 | €145M |
| DNA Script | Series C | Oct 2021 | €142M |
| Quell Therapeutics | Series B | Nov 2021 | €138M |
| Artios | Series C | Jul 2021 | €130M |
| DentalMonitoring | Other | Oct 2021 | €129M |
| MindMaze | Other | Oct 2021 | €108M |
| Touchlight | Other | Sep 2021 | €107M |
| Anaveon | Series B | Dec 2021 | €105M |
| Pepgen | Other | Aug 2021 | €95M |
| T-knife | Series B | Aug 2021 | €93M |
| bit.bio | Series B | Nov 2021 | €89M |
| Emergence Therapeutics | Other | Dec 2021 | €87M |
Top investors
most active in H2 2021, by deal count- Sofinnova Partners7 deals
- Verve Ventures7 deals
- BGF6 deals
- Calm Storm Ventures6 deals
- European Innovation Council (EIC)6 deals
- Octopus Ventures6 deals
- Boehringer Ingelheim Venture Fund5 deals
- Casdin Capital5 deals
- Kurma Partners5 deals
- LSP5 deals